chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a pharmacist concerning a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On an unknown date, the patient was vaccinated with ZOSTAVAX 19400 plaque-forming units (PFU) (dose, lot# and expiration date were not provided) in an unspecified arm. The reporter that was unsure if the vaccine was administered either by subcutaneous or intramuscular route. There were no concomitant medications reported. On an unknown date, the patient experienced injection site pain. No product quality complain was involved. At the reporting time, the outcome of the event of injection site pain was unknown. The reporter did not assessed the causality between the event of injection site pain and ZOSTAVAX. This is one of several reports from the same reporter. Additional information has been requested.
Fever, redness to right deltoid 4cm x 6.5cm. Benadryl 1.5tsp TID x 3 days. Tylenol/ Advil
Shingles (Herpes Zoster)  First sign on 04/25, Full Development by 04/30.  Rashes with Puffyfffy Bumps,very painful and burning
Adverse reaction; This spontaneous case was reported by a patient and describes the occurrence of ADVERSE REACTION (Adverse reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced ADVERSE REACTION (Adverse reaction). At the time of the report, ADVERSE REACTION (Adverse reaction) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 05-Apr-2021: Reporter contact information
Patient came to the site requesting 2nd dose of Pfizer. Pt confirmed with the nurse that he was given one dose on July 17th. After 2nd dose was administered today, patients spouse reported that this was actually his 3rd dose, because he was told that his first dose (5/14) which was given at a pharmacy was expired. He was also told that he needed to restart the series so he got his shot again at the same Pharmacy. Before this given information, there were no flagged vaccinations in the system and the nurse was allowed to proceed, since it stated second dose due date was today August 12th, 2021.  Vital signs were initiated when he was escorted to the observation area. Vitals were stable and was observed for 40 minutes. Did not experience any adverse reactions. Patient left the facility at 12:05 pm with his wife.
evening of the day of vaccination, patient had red face and red conjunctiva  on the day following vaccination, patient had fever, chills, unilateral throbbing headache, and nausea/ vomiting  These symptoms persisted to 4/14
Feeling uncomfortable; Cramps; Arm is aching; This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (Feeling uncomfortable), MUSCLE SPASMS (Cramps) and PAIN IN EXTREMITY (Arm is aching) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.  Concurrent medical conditions included Down's syndrome.   On 25-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, the patient experienced PAIN IN EXTREMITY (Arm is aching). On 26-Mar-2021, the patient experienced DISCOMFORT (Feeling uncomfortable) and MUSCLE SPASMS (Cramps). At the time of the report, DISCOMFORT (Feeling uncomfortable), MUSCLE SPASMS (Cramps) and PAIN IN EXTREMITY (Arm is aching) was resolving.            No concomitant medications were reported. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 11-May-2021: Reporter denied further follow-up and stated that patient was fine now.
Mother brought child to clinic on 2/10/20 d/t reaction to vaccines given on 2/6/20. Mother states both of the child's legs started bruising and a red rash appeared around the injection sites the same day of vaccination. Child also ran a fever of 101 the next day on 2/7/20 and she gave Tylenol which helped with the fever. Her temperature ran 99.9 throughout the day on 2/7/20 and eventually came down. The mother called an aunt who works with a pediatrician and also talked to an ER nurse who told her to bring child to clinic to report reaction to the vaccines. Upon examining the child both of her legs had redness, swelling, and was hard to touch. The right leg had more redness and swelling than the right leg. She was not running a fever and the child said she was not hurting. Instructed mother to continue to monitor for any more signs & symptoms and call us if they do not go away. Mother verbalized understanding.
Information has been received from a physician concerning a female pt. It was noted that the pt was hospitalized, treated and released in first week of 1/00 for "double pneumonia" which she developed in the last week of 12/99. On 1/18/00, the pt was vaccinated with pneumococcal vaccine 23 polyvalent. The pt stated that she has experienced a chronic sore throat since the vaccination and that the sore throat persisted. Additionally, on about 2/8/00, the pt experienced a painful, heavy feeling in her joints which has resolved. Unspecified medical attention was sought. Additional information has been requested.
Discharge Physician: DO Primary Care Physician: DO  Date of Admission: 12/12/2022 Discharge Date: 12/14/2022 COVID Positive Date: 12/12/2022 PRESENTING PROBLEM: AKI (acute kidney injury) [N17.9] Syncope, unspecified syncope type [R55] COVID [U07.1] COVID-19 [U07.1]   HOSPITAL COURSE: Patient is a 70yo male who presented to hospital with a fall from home suspicious for possible vasovagal reaction. He had been feeling poorly for a couple of days and recently had a positive COVID test.    In the ED, he had CT imaging of the head that ws negative for acute process, but labs showed AKI and some changes in urinalysis including proteinuria and microscopic hematuria. A d dimer was obtained once admitted that was positive, and a CTA was obtained given the patient's known COVID infection. This was negative for PE.    A renal ultrasound obtained the following day did not show any abnormalities, and the patient's labs improved.    Patient's baseline per ED is near Cre of 2.0, his cre was as high as 3.39, today it is stable at 2.83. Patient is noted to have secondary metabolic acidosis and has been started on sodium bicarb tabs. It was stressed to the patient that he needs to follow up and be evaluated by nephrology after discharge, a referral has been sent. Patient has also been instructed to remain off Lisinopril/Hctz. He also has been instructed to return to ED if he experiences a decrease in urine output, leg swelling, or shortness of breath.   Electrolytes were monitored and repleted PRN throughout the admission. Patient clinically improved and hemodynamically stable for discharge.  Discussed plan of care discharge with patient including outpatient follow-up PCP within 7 days. Patient voiced understanding was agreeable with plan of care discharge
red patch on her arm,  but the redness is slightly gone but the circle is still visible; swollen; somewhat itchy but the redness is slightly gone but the circle is still visible; somewhat itchy; little clammy; headache; fatigue; This spontaneous case was reported by a consumer and describes the occurrence of COLD SWEAT (little clammy), HEADACHE (headache), FATIGUE (fatigue), VACCINATION SITE ERYTHEMA (red patch on her arm,  but the redness is slightly gone but the circle is still visible) and VACCINATION SITE SWELLING (swollen) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 065F21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 17-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Nov-2021, the patient experienced COLD SWEAT (little clammy), HEADACHE (headache) and FATIGUE (fatigue). On an unknown date, the patient experienced VACCINATION SITE ERYTHEMA (red patch on her arm,  but the redness is slightly gone but the circle is still visible), VACCINATION SITE SWELLING (swollen), VACCINATION SITE RASH (somewhat itchy but the redness is slightly gone but the circle is still visible) and VACCINATION SITE PRURITUS (somewhat itchy). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and IBUPROFEN for Adverse event, at an unspecified dose and frequency. On 22-Nov-2021, COLD SWEAT (little clammy), HEADACHE (headache) and FATIGUE (fatigue) had resolved. At the time of the report, VACCINATION SITE ERYTHEMA (red patch on her arm,  but the redness is slightly gone but the circle is still visible), VACCINATION SITE SWELLING (swollen) and VACCINATION SITE RASH (somewhat itchy but the redness is slightly gone but the circle is still visible) was resolving and VACCINATION SITE PRURITUS (somewhat itchy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported
This case was reported by a pharmacist and described the occurrence of elevated creatine kinase value in a male subject of unspecified age who was vaccinated with HAVRIX (GlaxoSmithKline). On an unspecified date the subject received 1st dose of HAVRIX (unknown details). On 10 December 2011, at an unspecified time after vaccination with HAVRIX, the subject experienced elevated creatine kinase value. The pharmacist stated that the physician who asked him did not think "it could have been anything else that elevated the CK". The pharmacist also reported that he was unsure if the elevated creatine kinase value was the cause of the current hospital admission. No further details were provided. The subject was hospitalised. At the time of reporting the outcome of the event was unspecified.
Pt. was here on the 11th of November for his well child visit. I gave him the DTaP immunization and he is 7 years old. Pt. was not supposed to get a DTaP at 7 years old. I did call the CDC and did give me some recommendations. CDC recommendations were that we are going to count the dose of DTaP given at 7-10 years of age as the dose of Tdap for ages 11-12 years of age. Pt. does not need another dose for 10 years and at that time we will do the Td booster. Patients PCP agrees with CDC recommendations
throat and chest tightness; throat and chest tightness; Vaccine- Related Anxiety; This is a spontaneous report from a non-contactable other HCP. This other HCP reported for a patient that a 29-years-old female patient received first dose of bnt162b2 (Pfizer-Biontech COVID-19 Vaccine, solution for injection, Batch/Lot Number: EN6205), via an unspecified route of administration on an unspecified date, as 1st dose, single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced throat and chest tightness, vaccine- related anxiety on an unspecified date. It was reported as, during her 15-minute waiting period after the injection, the patient began to experience throat and chest tightness on an unspecified date. Did not provide detail about differential diagnosis vaccine- related anxiety (include miscellaneous mental health). Treatment included water and snacks for events. Response towards treatment was good. The patient was discharge, stable to go home and follow up with HCP. The outcome of the events throat and chest tightness was recovering and for vaccine- related anxiety was unknown.  No follow-up attempts are possible. No further information is expected.
Local reaction to left upper arm. Redness to area and patch about 5" x 3" erythema. No Tx. Necessary only observation and apply or take Benadryl.
menstrual cycle began 10 days after previous cycle; This is a spontaneous report from a contactable consumer, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0151) via an unspecified route of administration in the arm left on 03Apr2021 (at the age of 42-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient did not receive any medication within two weeks of vaccination. The patient previously took the first dose of BNT162b2 (BIONTECH COVID-19 mRNA VACCINE; lot number: UNKNOWN) via an unspecified route of administration on 26Feb2021 (at the age of 42-year-old) as a single dose for covid-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 04Apr2021 the patient experienced a menstrual cycle that began 10 days after the previous cycle. She was always had 28 days cycle and this cycle began at 10 days. The patient did not receive any treatment for the event. The clinical outcome of the event menstrual cycle began 10 days after the previous cycle was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
This spontaneous report was received from a registered nurse, concerning a patient of an unknown age and gender. There were no concurrent conditions, medical history, drug reactions, allergies or concomitant medications reported. On unspecified dates, the patient was vaccinated with the first, second and third dose of GARDASIL 9 injection (dose, frequency, route of administration, lot number and expiration date were not reported) for an unknown indication. On 05-JUN-2017, the patient received a fourth dose of GARDASIL 9 injection (dose, frequency and route of administration were not reported) lot # N001533 with an expiration date of 16-OCT-2019, for prophylaxis. No adverse effects were reported. Additional information has been requested.
felt kinda achy; 4mos now and it gotten worst in the joints/ Pain scale of 8-9/10 was noted every morning; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (felt kinda achy) and ARTHRALGIA (4mos now and it gotten worst in the joints/ Pain scale of 8-9/10 was noted every morning) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037K20A and 015M20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy and Latex allergy. Concomitant products included MULTIVITAMINS [ASCORBIC ACID;ERGOCALCIFEROL;FOLIC ACID;NICOTINAMIDE;PANTHENOL;RETINOL;RIBOFLAVIN;THIAMINE HYDROCHLORIDE] for an unknown indication.   On 19-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-May-2021, the patient experienced MYALGIA (felt kinda achy) and ARTHRALGIA (4mos now and it gotten worst in the joints/ Pain scale of 8-9/10 was noted every morning). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) at a dose of 800mg. At the time of the report, MYALGIA (felt kinda achy) outcome was unknown and ARTHRALGIA (4mos now and it gotten worst in the joints/ Pain scale of 8-9/10 was noted every morning) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications include Cholesterol medications and multivitamins for  an unknown indications.
Patient received 1st dose 2Apr2021 did not receive 2nd dose because she could not get in touch with the vaccination site; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient received 1st dose 2Apr2021 did not receive 2nd dose because she could not get in touch with the vaccination site) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient received 1st dose 2Apr2021 did not receive 2nd dose because she could not get in touch with the vaccination site). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient received 1st dose 2Apr2021 did not receive 2nd dose because she could not get in touch with the vaccination site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
During observation period, patient reported tasting a metal taste in her mouth and throat.  Requested water.  No other symptoms.  Extended observation period,  symptoms did not change, better or worse.  Pt requested further evaluation.  Escorted to Urgent Care on site.
On April 12th I experienced severe pain in my right arm, which progressed to my right leg and eventually my left arm.  I went to a local ER where they ruled out a stroke.  The pain continued and on April 18th I went to the ER.  They admitted me and ordered a catscan and MRI.  They diagnosed me with Transverse Myelitis and recomme//nded that I see a neurologist to get a definitive answer to whether this is MS or just a one time occurrence.  while there i was treated with steroids for 3 days which alleviated the pain.  i was also taken off all statins, given B12 and blood thinners.
Redness & warmth of left thigh where KINRIX was administered on 2/17/09
Erythema and induration at site of PROQUAD injection. Measured approx 3 cms in dia.
PATIENT REPORTED DEVELOPING A RED RASH LIKE APPEARANCE AROUND INJECTION SITE 2 DAYS FOLLOWING SHINGRIX ADMINISTRATION. RASH DEVELOPED IN THE EVENING BUT LOOKED MUCH BETTER IN THE MORNING, WAS MORE OF JUST REDNESS IN THE MORNING RATHER THAN RASH LIKE. TOOK BENADRYL AND CONTINUED TO IMPROVE.  REDNESS ACCOMPANIED BY ARM SORENESS WHICH HAS ALSO IMPROVED. COUNSELED PATIENT TO CONTINUE WITH BENADRYL FOR REDNESS, IBUPROFEN AND ICE PACK FOR SORENESS/SWELLING,  AND TO CALL IF SYMPTOMS WORSEN.
vaccine given 6 days post expiry; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (vaccine given 6 days post expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was reported.   This case was linked to  (Patient Link).
RN give IM injection on the left arm but the needle retracted prematurely resulting in vaccine leaking. Another dose administered on opposite arm.
Moderna vaccine was administered from a vial having been opened for over 12 hours; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna vaccine was administered from a vial having been opened for over 12 hours) in an 86-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter once. On 01-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna vaccine was administered from a vial having been opened for over 12 hours). On 01-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Moderna vaccine was administered from a vial having been opened for over 12 hours) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment information was provided by the reporter.
Pt has swelling and redness (20cmX20cm) Lt thigh mom noticed 20 mins. ago. (around 0105PM) Continually crying since swelling.
lack of focus; no energy; migraines; mental fog; This is a spontaneous report from a contactable consumer (patient) from a Pfizer sponsored program Pfizer RX Pathways.  A patient of unspecified age and gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, batch/lot number: EW0196) via an unspecified route of administration on 07Jun2021 as DOSE 2, SINGLE for COVID-19 immunisation. The patient's medical history and concomitant medications was not reported. The patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, batch/lot number: EW0171) via an unspecified route of administration on 17May2021 as DOSE 1 SINGLE for COVID-19 immunisation. The patient received both doses of vaccine. The patient had rather severe side effects to include lack of focus, no energy, migraines (increased), and mental fog. It had been over three weeks since his second dose. The patient was not recovered from the events.  Follow-up attempts are not possible. No expected further was information.
Both injections were given too high on the left shoulder on 11/26/2018. Patient experienced immediate severe pain, 10/10. The pain has lessened over time, but he continues to have sharp pain in the left shoulder up to 5/10. He saw his PCP on 12/7/2018 and was referred to Ortho. He saw the orthopedic surgeon on 1/3/2019 when plain films were negative and he was treated with Meloxicam. He did not have improvement, so returned to his PCP on 5/16/2019. MRI was ordered and showed mild to moderate diffuse thickening of the subacromial subdeltoid bursa, that may represent infectious/inflammatory bursitis. Reactive versus possible. Mild erosive changes in the lateral aspect of the greater tuberosity. Possible mild tendinosis or low-grade interstitial tearing in the anterior infraspinatus tendon. The supraspinatous and subscapularis tendons are intact. No articular or bursal sided rotator cuff tear. He started Physical Therapy for left shoulder impingement/bursitis on 6/11/2019. He was referred back to the orthopedic surgeon on 6/12/2019 and markers of inflammation were collected.   He will see the orthopedic surgeon again, and physical therapy will continue.
After the pharmacist gave me my 2nd dose of the Moderna. He said to me, "Everyone is on their 3rd dose so I'll be back with another dose so you'd be receiving 2- 2.5 doses of the Moderna". I asked him while concerned, "shouldn't I wait for the 3rd shot".  The pharmacist said to me firmly, "No, you should have it now"! So he went to get another dose of the Moderna and gave me another shot. He did not record the 3rd shot on my vaccine card. I was going for just my 2nd dose of Moderna! However, this pharmacist had given me 2 doses of Moderna in 1 setting. Migraines, body soreness, and stiffness, with fatigue.
Patient received a higher concentration of Pfizer covid vaccine.  RN diluted the vial with 0.8 ml NS instead of 1.8 ml NS.  No negative outcome observed.